Drug intelligence / Profile preview

DAC HIV

Development stage: Preclinical
Lead developer: ConjuChem
Modality: Peptides, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Oral, Intramuscular

Overview

DAC HIV is a long-lasting drug conjugate developed by ConjuChem LLC for the treatment of HIV infections. It targets the gp41 protein, which is crucial for the HIV virus's membrane fusion and infection process. The drug utilizes a C34 peptide, known to block virus-mediated cell-to-cell fusion and de novo HIV-1 infection of T-cells. ConjuChem's proprietary DAC™ technology is applied to this C34 peptide to increase its plasma residence time, thereby sustaining its antiviral activity and potentially preventing the development of viral resistance. The drug is currently in the preclinical phase of development.

Other names: DAC™: HIV conjugate

Targets

HIV-1 gp41 NHR (HIV-1 gp41 N-terminal heptad repeat region)

Beyond the preview

Go deeper on DAC HIV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DAC HIV.

Explore the full profile